C-225 epidermal growth factor receptor: IMCL began a third Phase Ia/IIb trial

ImClone Systems Inc. (IMCL), New York, N.Y. Product: C-225 epidermal growth factor receptor (EGFr) antagonist Indication: EGFr-positive breast cancer Status: IMCL began a third Phase Ia/IIb trial wit...